(CIX: WRAL30)  1,163.58  down arrow-23.29  (-1.96 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: Apple)  124.53  down arrow-2.22  (-1.75 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NY: QUINTILES)  72.08  down arrow-1.17  (-1.6 %)  Updated: 06:40 PM EDT, Jun 29 2015
(OP: BASF SE)  89.23  down arrow-3.65  (-3.93 %)  Updated: 05:20 PM EDT, Jun 29 2015
(NQ: BioCryst)  14.42  down arrow-0.2  (-1.37 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: BioDelivery)  7.26  down arrow-0.43  (-5.59 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: CEMP)  31.96  down arrow-1.93  (-5.69 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: Cisco Systems)  27.54  down arrow-0.74  (-2.62 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: Cree)  25.96  down arrow-1.04  (-3.85 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: DARA)  0.88  down arrow-0.02  (-2.08 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NY: EMC CORPORATION)  25.99  down arrow-0.46  (-1.74 %)  Updated: 06:40 PM EDT, Jun 29 2015
(NQ: Extreme Networks)  2.65  down arrow-0.11  (-3.99 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: FB)  85.80  down arrow-2.21  (-2.51 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NY: GLAXOSMITHKLINE)  42.03  down arrow-0.86  (-2.01 %)  Updated: 06:40 PM EDT, Jun 29 2015
(NQ: GOOG)  521.52  down arrow-10.17  (-1.91 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NY: IBM)  162.97  down arrow-2.49  (-1.5 %)  Updated: 06:40 PM EDT, Jun 29 2015
(NY: LH)  119.39  down arrow-2.23  (-1.83 %)  Updated: 06:40 PM EDT, Jun 29 2015
(OP: Lenovo Group)  26.51  down arrow-1.74  (-6.15 %)  Updated: 05:20 PM EDT, Jun 29 2015
(NY: MRK)  57.29  down arrow-1.2  (-2.05 %)  Updated: 06:40 PM EDT, Jun 29 2015
(NQ: Microsoft Corp)  44.37  down arrow-0.89  (-1.97 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: NTAP)  31.68  down arrow-0.69  (-2.12 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NY: NOVARTIS AG)  98.53  down arrow-1.39  (-1.39 %)  Updated: 06:40 PM EDT, Jun 29 2015
(OP: Novozymes A/S)  48.13  down arrow-1.16  (-2.34 %)  Updated: 05:20 PM EDT, Jun 29 2015
(NY: PFIZER)  33.59  down arrow-0.33  (-0.97 %)  Updated: 06:40 PM EDT, Jun 29 2015
(NQ: Pozen)  10.45  down arrow-0.56  (-5.09 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NY: RED HAT)  75.45  down arrow-2.03  (-2.62 %)  Updated: 06:40 PM EDT, Jun 29 2015
(NQ: BBRY)  8.29  down arrow-0.28  (-3.27 %)  Updated: 08:10 PM EDT, Jun 29 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  14.69  down arrow-0.29  (-1.94 %)  Updated: 08:10 PM EDT, Jun 29 2015

Posts tagged “GSK”

June 22

GSK sells 2 vaccines to Pfizer; Google 'revenge porn' crackdown; Tesla for the sky; Polish airline hack; eBay, Craigslist settle

Bulldog In today's Bulldog wrapup of tech and life science news: GSK is selling two meningitis vaccines to Pfizer; Google cracks down on "revenge porn;' a Tesla for the skies?; Polish airline is hacked; and eBay settles a dispute with Craigslist.

June 16

GSK funds 3 startups; Congress eyes data breach; risk; facial recognition debate; Triangle Cleantech update

Bulldog In today's Bulldog wrapup of technology and life science news: GlaxoSmithKline is funding three more startups at an incubator in San Diego; Congress looking into huge federal data breach; is data at risk?; facial recognition standards talks hit a roadblock; and an added position for the head of the Research Triangle Cleantech Cluster.

June 12

GSK's good news: FDA panel OKs asthma drug; cervical cancer vaccine in one dose

GSK   Drug giant GlaxoSmithKline received two doses of good news this week. An FDA committee on Thursday recommended its drug be approved for use in adults. Plus a new study says a cervical cancer vaccine appears effective with one dose.

May 20

Premium Lock 'Introducing PfizerKline'? Wall Street analysts sees Pfizer buying GSK

Pfizer  Where there is smoke is there fire when it comes to rumors that Pfizer might try to buy troubled GlaxoSmithKline? A Wall Street analyst is the latest to speculate that a mega merger could be in the works.

Updated May 11

Premium Lock GSK, UNC-Chapel Hill form company to seek HIV cure

Drug giant GlaxoSmithKline is teaming up with the University of North Carolina at Chapel Hill in an attempt to find a cure for AIDS. The two will form a new company called Qura Therapeutics and will launch an "HIV Cure Center" in Chapel Hill. GSK is committing $20 million over the next five years to fund the project.

May 7

Premium Lock New GSK board chair expresses support for CEO Witty

GSK's HQ in London           The new executive chair of GlaxoSmithKline came out in support of CEO Andrew Witty on Thursday, a day after Witty disclosed his strategy for bolstering the drug giant's future. "Andrew has the complete support of the board," said Philip Hampton. GSK also disclosed its new board lineup.

Updated May 7

Premium Lock GSK won't spin off its HIV business, cuts Novartis deal return to shareholder

Andrew Witty      As a new chair prepares to take over at GlaxoSmithKline, the drug giant says it will not spin off its majority holdings in a promising HIV drug developer. CEO Andrew Witty also says GSK won't return as much of the profits from its big deal with Novartis to shareholders.

May 1

Premium Lock FDA approves expansion of GSK inhaler to fight asthma

GSK   ​GlaxoSmithKline has received U.S. approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older.

April 30

Premium Lock Quintiles, Biogen, Martin Marietta, GSK, Pfizer, Merck crack InformationWeek elite list

InformationWeek's annual "Elite 100" corporate list for innovative technology includes several located in or have big operations around the Triangle as well as the City of Asheville.

The Elite 100 The Elite 100

Updated April 30

Premium Lock Uber eyes deliveries; IBM' quantum computing advance; Yahoo CEO pay surges; GSK targets shingles; genetic testing for insurance?

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Uber eyes making deliveries; IBM reports an advance in quantum computing; pay for Yahoo CEO surges; GSK's shingles drug shows promise; and are genetic tests for insurance in your future?

April 27

Premium Lock Report: 'Strong likelihood' Pfizer may try to acquire GSK

Pfizer  Drug giant Pfizer, which failed a year ago in its attempt to acquire AstraZeneca, may now be targeting GlaxoSmithKline as a takeover target, according to business news site BidnessEtc. Pfizer has steadily increased its North Carolina presence in recent years, and GSK employs thousands in the Triangle.

April 24

Premium Lock GSK malaria vaccine nearer OK; Aerie not giving up on glaucoma treatment; Duke Energy's Greentech award; Novartis soars; CDC's new tech tracks listeria

Bulldog In the latest wrapup of technology and life science news: GSK's malaria vaccine is closer to approval after clinical trial; Aerie Pharmaceuticals not giving up on glaucoma treatment; Duke Energy wins a Greentech award; Novartis soars in wake of GSK, Eli Lilly deals; CDC uses new tech to track listeria illnesses.

April 16

Premium Lock Report: GSK shutting Pittsburgh office, eliminating 274 jobs

Layoffs        Drug giant GlaxoSmithKline, which already is cutting hundreds of jobs in the Triangle and in the Philadelphia area, is now in the process of closing an office in Pittsburgh where 274 people work, according to the Pittsburgh Business Times.

April 13

Premium Lock GSK considers revamping compensation plan for sales force

GSK   Drug giant GlaxoSmithKline is considering making changes in the way its sales force is compensated, according to an internal memo obtained by Bloomberg News and The Wall Street Journal.

April 3

Premium Lock GSK picks Maryland for vaccine research and development center

Drug giant GlaxoSmithKline, which is laying off hundreds of people in Research Triangle Park and Pennsylvania, is going to build a new research and development center for vaccines in Maryland.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

Updated March 25

Premium Lock Google Fiber expands; Jim Goodnight's venture play; non-GMO food label; new Instagram app; GSK's next HQ in Asia

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Google Fiber is expanding; Jim Goodnight's new venture play is biotech; a proposed label for non-GMO foods; Instagram has a new app; and GSK is building a new Asian headquarters.

March 25

Premium Lock Life beyond GSK: The entrepreneurial career options

Biotech   At an event put on by the North Carolina Biotechnology Center and supported by GlaxoSmithKline, more than 300 people who are losing their jobs at GSK through layoffs gathered to hear about possible options for future employment. "There is life beyond GSK," former GlaxoWellcome CEO Robert Ingram tells the crowd.

Updated March 23

Premium Lock Glaxo plans 180 layoffs in Durham

GSK's HQ in London GlaxoSmithKline notified the state Monday that it plans to eliminate 180 jobs at its Durham offices effective June 1.

Tags: Layoffs, GSK
March 20

Premium Lock Despite Bill Gates' warning, will world prepare for the next Ebola?

Bill Gates The Bill & Melinda Gates Foundation took a major role in trying to find a vaccine to treat Ebola, even providing funding to Durham-based Chimerix. Now, Bill Gates is warning that the world must prepare for future epidemics. If we are smart, we will listen and learn from what's happened from an outbreak that has killed some 10,000 people.

March 20

Premium Lock AT&T's $40M error; GSK job cuts; Amazon 1-hour delivery; Salix $78M parachutes; GSK inhaler; China freedom group attacked

Bulldog In today's Bulldog wrapup of technology and life science news: AT&T takes a $40M hit in a lawsuit; GSK is cutting 150 jobs in Pa.; Amazon expands 1-hour delivery service; Salix handing out $78M in golden parachutes; GSK wins OK for inhaler; and a China web freedom group is under attack.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith